ArticleBMC infectious diseases2025
Antimicrobial resistance of uropathogens in diabetic patients.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Resistance Landscape of Uropathogens in a Romanian Tertiary Center: A 13-Month Single-Center Study with Focus onMicroorganisms · 2026Article
- Genomic and socioeconomic drivers of antimicrobial resistance forecast to 2050.Cell genomics · 2026Article
- Feeding the invaders: how metabolic imbalance shapes infection and biofilm development.FEMS microbiology reviews · 2026Review
- Urinary tract infections in diabetes: clinical significance and management approaches.Acta biochimica Polonica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with Diabetes mellitus (DM) have higher rates of urinary tract infections (UTIs). This study evaluated the antimicrobial resistance (AMR) of uropathogens and whether uropathogens isolated from DM patients exhibit greater AMR.
methodsA cross-sectional multicenter study included adults with UTI symptoms and a positive urine culture from December 2020 to January 2021. Patients were categorized into uncomplicated UTI (G1, n = 133), complicated UTI without (G2, n = 215), or with DM (G3, n = 217). Patient data, microbiology results, and associations between DM, antibiotic resistance, and bacterial isolates were analyzed using Kruskal-Wallis followed by Dunn's multiple comparisons or Fisher's exact test, as appropriate.
resultsE. coli from the complicated UTI groups G2 and G3 were resistant to more antibiotics and antibiotic classes, with a higher percentage of non- E. coli isolates than G1. The percentage of multidrug-resistant E. coli in G1, G2, and G3 was 30.5%, 61.8%, and 59.0%, respectively. In G1, resistance to fluoroquinolones and trimethoprim-sulfamethoxazole exceeded 20%, but remained below 20% for nitrofurantoin and fosfomycin. Although G2 and G3 had similar resistance profiles, differences occurred for specific antibiotics. E. coli from G3 exhibited higher resistance to nitrofurantoin (10.2% vs. 34.3%, p-value < 0.001) and piperacillin-tazobactam (31.3% vs. 16.6%, p-value = 0.061). In contrast, G2 Uropathogens had higher resistance to nalidixic acid, norfloxacin, and ofloxacin compared to G3.
conclusionThese findings suggest a possible association between DM and the chance of recovering an isolate resistant to nitrofurantoin. Stratifying patients by risk factors like DM could improve empiric therapy outcomes and contribute to reducing AMR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.